Anti-VEGF therapy may act synergistically in combination with novel therapeutics to contribute to disease response, although thus far a benefit of anti-VEGF therapy has not been observed in larger phase III trials in pancreatic cancer. The gene discussed is VEGFA; the disease is familial pancreatic carcinoma.